Saphnelo can now be administered subcutaneously rather than intravenously following the European regulator’s recommendation.
SinoMab Bioscience Ltd. ( ($HK:3681) ) has shared an update. SinoMab BioScience Limited announced the successful dosing of the first cohort of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback